ArticleAnnals of nuclear medicine2026
Prognostic value of whole-body tumor SUV dispersion on baseline PSMA PET prior to PSMA radioligand therapy.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- Artificial intelligence across oncologic theranostics: evidence for patient stratification, dosimetry, and adaptive radiopharmaceutical therapy.Frontiers in nuclear medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective single-center study evaluated and compared the prognostic value of distribution parameters of standardized uptake value (SUV) in whole-body tumor volume (WTV) on PSMA PET/CT prior to 177Lu-PSMA radioligand therapy (PSMA RLT) for early treatment response and overall survival (OS).
methodsFor 59 patients with metastatic castration-resistant prostate cancer baseline clinical and PSMA PET/CT characteristics (Gleason score, time-to-therapy, age, PSA, prior therapies, metastasis sites, WTV) and SUV distribution parameters in WTV (SUVmean, SUVmedian, SUVmax, skewness, kurtosis and interquartile range (IQR)) prior to PSMA RLT were retrospectively collected. The prognostic value for early biochemical and/or imaging progression (PD) (according to PCWG3 and RECIP) as well as OS was evaluated using univariate logistic or Cox regression. SUV distribution parameters significant in univariate analyses were further evaluated using multivariate logistic or Cox regression adjusted for significant baseline characteristics. Model performance was assessed by cross-validation (5-folds, 10 repeats), quantified by area under the curve (AUC) and Harrell’s C, and compared with Wilcoxon signed-rank tests. Addition of other parameters into a regression model was assessed with likelihood ratio tests.
results31 patients (53%) showed early PD after 2 cycles. Median follow up was 20 [2–38] months, with 18 patients (31%) being alive at last follow-up. Univariately, PD correlated with age, prior chemotherapy (CTx), SUVmean, SUVmedian, SUVmax and IQR (p ≤ 0.05) while OS correlated with SUVmean, SUVmedian, SUVmax, IQR (p ≤ 0.01) as well as age on a trending level (p = 0.06). IQR was more predictive of PD (AUC 0.95 [0.8-1.0], p < 0.001, corrected for age and CTx) and OS (C 0.8 [0.62–0.97], p < 0.001, corrected for age) compared to SUVmean (AUC 0.86 [0.58-1.0] ; C 0.66 [0.41–0.87]), SUVmedian (AUC 0.86 [0.66-1.0]; C 0.61 [0.36–0.92]) and SUVmax (AUC 0.84 [0.59-1.0]; C 0.63 [0.44–0.88]). Adding SUVmean, SUVmedian or SUVmax to the IQR regression model did not significantly increase its predictive value for PD or OS (p ≥ 0.27).
conclusionsOn PSMA PET/CT before PSMA RLT the dispersion parameter IQR of the SUV distribution in WTV demonstrates strong potential for predicting early progression and overall survival and surpasses the prognostic value of established measures of central tendency (SUVmean and SUVmedian) and SUVmax.
Indexed as
Identifiers
41348287What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.